Physicians to Gain Streamlined, Secure Access to RxCentric's Services,
Such as Profiling of Drug Safety and Efficacy Benefits
CHICAGO and MOUNTAIN VIEW, Calif., July 16 /PRNewswire/ --
The American Medical Association (AMA) and VeriSign, Inc. (Nasdaq: VRSN), the leading provider of Internet trust services, today announced that RxCentric Inc, a leading provider of physician relationship management solutions to the pharmaceutical industry, will enable its online services to accept AMA Internet IDs so that physicians can securely access online data and services with a single digital credential. The agreement represents the first major pharmaceutical marketing application to enable a higher level of security and privacy for such services as online detailing and market research.
Physicians routinely cite security as their main concern in using the Internet to communicate and conduct transactions. With the AMA Internet ID Service, physicians can more fully realize the potential of the Internet by securely accessing a wide range of clinical and administrative Web-based applications such as claims, patient charting, pharmaceutical product information, and e-prescriptions. Since physicians conduct business in a variety of places including offices, hospitals and home offices, the service will feature roaming capabilities to give physicians the freedom to perform online tasks securely from any location.
"As new applications such as these begin to accept AMA Internet IDs, physicians can put their passwords on a shelf and benefit from secure and easy access to online services from filing claims, finding leading information on pharmaceutical products, and filling e-prescriptions," said Robert A. Musacchio, Ph.D., AMA senior vice president of publishing, business and membership.
"We look forward to working closely with the AMA and VeriSign to provide our pharmaceutical partners, and the physicians with whom we interact online, a more secure platform for new product and content information that will lead to the enhancement of patient care," said Richard Findlay, CEO and president of RxCentric. "Our relationship with the AMA and VeriSign underscores RxCentric's commitment to delivering the next generation of services."
The AMA and VeriSign announced in April a partnership to enhance the AMA Internet ID Service and help develop applications that can utilize AMA Internet IDs. AMA Internet IDs provide physicians with a single digital credential that enables secure access to a number of online applications without having to remember multiple passwords. With higher levels of authentication, AMA Internet IDs can also be used in applications that include physician- and patient-sensitive content.
RxCentric's e-detailing product enables pharmaceutical companies to profile a drug's safety and efficacy benefits for a targeted group of physicians via the Internet, thereby complementing the pharmaceutical company's offline sales campaigns. RxCentric's use of the AMA Internet ID Service will enhance this process, assuring pharmaceutical companies that the physicians who participate in the e-detailing and other online marketing programs are properly authenticated.
The enhanced AMA Internet ID Service will be the first Internet authentication offering built on VeriSign's next generation trust services, which provide a standards-based, open framework that makes it easy for developers to integrate advanced security functions into online applications. VeriSign's managed trust services are designed to rapidly assist health care organizations and application vendors in their efforts to comply with the proposed Health Insurance Portability and Accountability Act (HIPAA) regulations.
Availability
The AMA's Internet ID Service is available today and the enhanced service is scheduled for availability in the third quarter. The new secure e-mail services and digital signature handling capability will be available as part of the service in the third quarter.
About the American Medical Association
Founded 154 years ago, the American Medical Association is the largest medical association in the world and is the nation's principal advocate for patients and their physicians. It sets standards for the profession of medicine and is an influential leader in the continuing national debate over health care. The AMA's work includes the development and promotion of standards in medical practice, research and education; a strong advocacy agenda on behalf of patients and physicians; and the commitment to provide accurate, timely information and discourse on matters important to the health of America. For more information, please visit www.ama-assn.org .
About VeriSign
VeriSign, Inc. (Nasdaq: VRSN) is the leading provider of trusted infrastructure services to Web sites, enterprises, electronic commerce service providers and individuals. The company's domain name, digital certificate and payment services provide the critical Web identity, authentication and transaction infrastructure that online businesses require to conduct secure e-commerce and communications. VeriSign's services are available through its Web site ( www.verisign.com ) or through its direct sales force and reseller partners around the world.
About RxCentric
RxCentric Inc. ( www.rxcentric.com ) is a leading Internet Marketing Solutions Provider for the pharmaceutical industry, providing customized and targeted online product marketing capability that extends the reach and frequency of existing offline marketing and sales activities. RxCentric's promotional and educational services include online detailing and sampling, online continuing medical education (CME) programs, as well as market research and sales representative support. RxCentric provides pharmaceutical partners unprecedented access to a nationally representative population of more than 27,000 prescribing physicians through its free, physician-only ISP service called Doctors Net Access (DNA). The DNA service consists of seven medical specialty channels: Allergy, Cardiology, Neurology, Oncology/Hematology, Primary Care, Pulmonary Medicine and Urology. RxCentric Inc. is a privately held company with locations in New York, Morristown N.J., Philadelphia and San Diego.
Statements in this announcement other than historical data and information constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve risks and uncertainties that could cause VeriSign's actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include, among others, VeriSign's limited operating history under its current business structure, uncertainty of future revenue and profitability and potential fluctuations in quarterly operating results, increased competition, risks associated with the company's international business and risks related to potential security breaches. More information about potential factors that could affect the company's business and financial results is included in VeriSign's filings with the Securities and Exchange Commission, especially in the company's Annual Report on Form 10-K for the year ended December 31, 2000 and its Quarterly Report on Form 10-Q for the period ended March 31, 2001. VeriSign undertakes no obligation to update any of the forward-looking statements after the date of this press release.
VeriSign is a registered trademark of VeriSign, Inc. RxCentric is a registered trademark of RxCentric Inc. Other names may be trademarks of their respective owners.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X38318616
No comments:
Post a Comment